Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

被引：6
|
作者：
Hotta, Katsuyuki [1 ,2 ]
Ninomiya, Kiichiro [1 ]
Ichihara, Eiki [1 ]
Kiura, Katsuyuki [1 ]
机构：
[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[2] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan
来源：
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 24卷 / 01期
基金：
日本学术振兴会;
关键词：
Lung cancer; Treatment; Re-biopsy; CISPLATIN-BASED CHEMOTHERAPY; LOW-VOLUME HYDRATION; SPATIOTEMPORAL T790M HETEROGENEITY; EGFR-MUTANT; PROSPECTIVE FEASIBILITY; OPEN-LABEL; EXPRESSION; MUTATIONS; ALECTINIB; 1ST-LINE;
D O I：
10.1007/s10147-018-1344-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. Thisreview reports that the significance of a re-biopsy varies depending on the clinical situation.
引用
收藏
页码：41 / 45
页数：5
相关论文
共 50 条
  • [31] Tumor evolution in non-small-cell lung cancer
    Parry, Marina
    ESMO OPEN, 2018, 3 (06)
  • [32] The Tumor Microenvironment in Non-Small-Cell Lung Cancer
    Graves, Edward E.
    Maity, Amit
    Le, Quynh-Thu
    SEMINARS IN RADIATION ONCOLOGY, 2010, 20 (03) : 156 - 163
  • [33] Significance of preoperative biopsy in radiological solid-dominant clinical stage I non-small-cell lung cancer
    Huang, Chien-Sheng
    Chien, Hung-Che
    Chen, Chun-Ku
    Yeh, Yi-Chen
    Hsu, Po-Kuei
    Chen, Hui-Shan
    Hsieh, Chih-Cheng
    Hsu, Han-Shui
    Huang, Biing-Shiun
    Shih, Chun-Che
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2021, 32 (04) : 537 - 545
  • [34] The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer
    Bozyk, Aleksandra
    Nicos, Marcin
    LIFE-BASEL, 2022, 12 (10):
  • [35] Experience of Re-Biopsy (Biopsy at Progression) of EGFR Mutant Non-Small Cell Lung Cancer Patients in Japan: A Retrospective Study
    Nosaki, Kaname
    Satouchi, Miyako
    Kurata, Takayasu
    Yoshida, Tatsuya
    Okamoto, Isamu
    Katakami, Nobuyuki
    Imamura, Fumio
    Tanaka, Kaoru
    Tashiro, Naoki
    Seto, Takashi
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1250 - S1251
  • [36] Evaluation of advanced non-small-cell lung cancer (ANSCLC) chemotherapy in routine practice
    Jouveshomme, S
    Hermant, P
    Patte, D
    REVUE DES MALADIES RESPIRATOIRES, 2004, 21 (04) : 719 - 726
  • [37] Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
    Faehling, M.
    Eckert, R.
    Kuom, S.
    Kamp, T.
    Stoiber, K.
    Kropf, C.
    Ruediger, S.
    Schumann, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 550 - 551
  • [38] Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients
    Kano, Hirohisa
    Kubo, Toshio
    Ninomiya, Kiichiro
    Ichihara, Eiki
    Ohashi, Kadoaki
    Rai, Kammei
    Hotta, Katsuyuki
    Tabata, Masahiro
    Hiraki, Takao
    Kanazawa, Susumu
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    RESPIRATORY INVESTIGATION, 2021, 59 (02) : 240 - 246
  • [39] Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice
    Tassinari, D.
    Drudi, F.
    Lazzari-Agli, L.
    Tombesi, P.
    Sartori, S.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 428 - 429
  • [40] Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
    Faehling, Martin
    Eckert, Robert
    Kuom, Sabine
    Kamp, Torsten
    Stoiber, Kathrin
    Kropf, C.
    Ruediger, S.
    Schumann, Christian
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S711 - S712
12345